Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIAN
2022-501894-37-00Phase 2Authorised
- Sponsor
- Fondazione Radioterapia Oncologica
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Fondazione Radioterapia Oncologica. Primary endpoint: Complete biochemical response rate at 6 months. Planned start Mar 2023; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-501894-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501894-37-00.